Intest Res.  2023 Jul;21(3):406-410. 10.5217/ir.2022.00125.

Clinical features of enteric and colo-duodenal fistula in patients with Crohn’s disease

• Lee JS
• Kang SB
• Park K
• Yoon YS
• Yu CS
• Hwang SW
• Ye BD
• Yang SK
• Lee JL
• Park SH

• KMID: 2544763
• DOI: http://doi.org/10.5217/ir.2022.00125

Figure

• 

  Fig. 1. Endoscopic and radiologic findings of enteric and coloduodenal fistula (ECDF) in Crohn’s disease. (A, B) ECDF (black arrow) on esophagogastroduodenoscopy. (C, D) ECDF (ref arrow) on computed tomography scan.

Reference

1. Hisamatsu T, Suzuki Y, Kobayashi M, et al. Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study. Intest Res. 2021; 19:408–418.

2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004; 350:876–885.

3. Yoon YS, Yu CS, Yang SK, Yoon SN, Lim SB, Kim JC. Intra-abdominal fistulas in surgically treated Crohn’s disease patients. World J Surg. 2010; 34:1924–1929.

4. El-Hajj II, Abdul-Baki H, El-Zahabi LM, Barada KA. Primary coloduodenal fistula in Crohn’s disease. Dig Dis Sci. 2007; 52:59–63.

5. Gong J, Wei Y, Gu L, et al. Outcome of surgery for coloduodenal fistula in Crohn’s disease. J Gastrointest Surg. 2016; 20:976–984.

6. Pichney LS, Fantry GT, Graham SM. Gastrocolic and duodenocolic fistulas in Crohn’s disease. J Clin Gastroenterol. 1992; 15:205–211.

7. Kotze PG, Coy CS. The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn’s disease: controversy still persists. Am J Gastroenterol. 2014; 109:139.

8. Freund MR, Perets M, Horesh N, et al. Prevalence, diagnosis, and surgical management of complex ileocolic-duodenal fistulas in Crohn’s disease. Tech Coloproctol. 2022; 26:637–643.

9. Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006; 24:1283–1293.

10. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995; 123:132–142.

11. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn’s disease: an ACCENT-II post hoc analysis. Am J Gastroenterol. 2021; 116:1007–1014.